- Home
- LAUR vs RNA Comparison
LAUR vs RNA Comparison
Compare LAUR & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAUR
- RNA
- Stock Information
- Founded
- LAUR 1989
- RNA 2012
- Country
- LAUR United States
- RNA United States
- Employees
- LAUR N/A
- RNA N/A
- Industry
- LAUR Other Consumer Services
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- LAUR Real Estate
- RNA Health Care
- Exchange
- LAUR Nasdaq
- RNA Nasdaq
- Market Cap
- LAUR 2.8B
- RNA 3.2B
- IPO Year
- LAUR 2017
- RNA 2020
- Fundamental
- Price
- LAUR $19.14
- RNA $26.66
- Analyst Decision
- LAUR Buy
- RNA Strong Buy
- Analyst Count
- LAUR 2
- RNA 12
- Target Price
- LAUR $20.00
- RNA $68.25
- AVG Volume (30 Days)
- LAUR 989.4K
- RNA 1.9M
- Earning Date
- LAUR 05-01-2025
- RNA 05-08-2025
- Dividend Yield
- LAUR N/A
- RNA N/A
- EPS Growth
- LAUR 183.74
- RNA N/A
- EPS
- LAUR 1.92
- RNA N/A
- Revenue
- LAUR $1,566,642,000.00
- RNA $10,897,000.00
- Revenue This Year
- LAUR $2.07
- RNA N/A
- Revenue Next Year
- LAUR $6.82
- RNA $135.33
- P/E Ratio
- LAUR $9.97
- RNA N/A
- Revenue Growth
- LAUR 5.55
- RNA 13.98
- 52 Week Low
- LAUR $13.26
- RNA $21.51
- 52 Week High
- LAUR $21.73
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- LAUR 45.86
- RNA 45.21
- Support Level
- LAUR $18.06
- RNA $25.28
- Resistance Level
- LAUR $19.58
- RNA $27.67
- Average True Range (ATR)
- LAUR 0.79
- RNA 2.36
- MACD
- LAUR -0.06
- RNA -0.03
- Stochastic Oscillator
- LAUR 41.45
- RNA 56.41
About LAUR Laureate Education Inc.
Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its geographical segments include Peru and Mexico.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.